DUBLIN – The EMA's Committee for Human Medicinal Products (CHMP) diverged from the FDA in its response to an application from the European arm of Emmaus Medical Inc., for approval of Xyndari, an oral formulation of the amino acid glutamine, for treating sickle cell disease.